S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:SVRA

Savara Stock Forecast, Price & News

$1.70
-0.10 (-5.56 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.70
Now: $1.70
$1.90
50-Day Range
$1.31
MA: $1.67
$2.06
52-Week Range
$1.00
Now: $1.70
$3.17
Volume453,121 shs
Average Volume618,991 shs
Market Capitalization$92.04 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Savara logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SVRA
CUSIPN/A
Phone512-614-1848
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$6.54 per share
Book Value$2.47 per share

Profitability

Net Income$-78,170,000.00

Miscellaneous

Market Cap$92.04 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

84th out of 1,960 stocks

Pharmaceutical Preparations Industry

31st out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
$1.70
-0.10 (-5.56 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Savara (NASDAQ:SVRA) Frequently Asked Questions

Is Savara a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Savara stock.
View analyst ratings for Savara
or view top-rated stocks.

What stocks does MarketBeat like better than Savara?

Wall Street analysts have given Savara a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Savara wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Savara
.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) posted its quarterly earnings data on Thursday, November, 5th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The company had revenue of $0.26 million for the quarter.
View Savara's earnings history
.

How has Savara's stock price been impacted by Coronavirus?

Savara's stock was trading at $2.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SVRA stock has decreased by 28.0% and is now trading at $1.70.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SVRA?

2 analysts have issued 1 year price targets for Savara's stock. Their forecasts range from $3.00 to $3.00. On average, they expect Savara's stock price to reach $3.00 in the next year. This suggests a possible upside of 76.5% from the stock's current price.
View analysts' price targets for Savara
or view top-rated stocks among Wall Street analysts.

Who are Savara's key executives?

Savara's management team includes the following people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

Who are some of Savara's key competitors?

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.56%), Northern Trust Corp (0.93%), Renaissance Technologies LLC (0.74%), JPMorgan Chase & Co. (0.27%), Brown Advisory Inc. (0.21%) and Dimensional Fund Advisors LP (0.20%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Matthew Pauls and Richard J Hawkins.
View institutional ownership trends for Savara
.

Which major investors are selling Savara stock?

SVRA stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Dimensional Fund Advisors LP, and Northern Trust Corp.
View insider buying and selling activity for Savara
or view top insider-selling stocks.

Which major investors are buying Savara stock?

SVRA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Brown Advisory Inc., Renaissance Technologies LLC, and Rhumbline Advisers. Company insiders that have bought Savara stock in the last two years include David A Ramsay, and Matthew Pauls.
View insider buying and selling activity for Savara
or or view top insider-buying stocks.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $1.70.

How much money does Savara make?

Savara has a market capitalization of $92.04 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.

What is Savara's official website?

The official website for Savara is www.savarapharma.com.

Where are Savara's headquarters?

Savara is headquartered at 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.